An early study across multiple clinical trials in advanced breast, cervical, endometrial, and ovarian cancers showed a higher response to PI3K/mTOR inhibitors in patients with PIK3CA mutations versus patients without mutations [62]. Here, PIK3CA is linked to ovarian cancer.